DCGO
DocGo Inc.
DCGO lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
DCGO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Strong |
DCGO's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are weak.
DCGO PE Valuation
DCGO has no meaningful PE right now: it lost money over the past year.
DCGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect DCGO's losses to shrink, with revenue holding steady. However, they disagree widely on these estimates.
DCGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.84 | -$1.33 |
| Q2 2026 | -$1.95 | -$1.77 |
| Q1 2026 | -$1.90 | -$1.89 |
| Q4 2025 | -$1.84 | -1122% |
| Q3 2025 | -$0.51 | -289% |
| Q2 2025 | -$0.18 | -167% |
| Q1 2025 | -$0.01 | -105% |
| Q4 2024 | $0.18 | +200% |
DCGO lost $1.84 per share over the past year, a bigger loss than the year before.
DCGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $73.4M | +3.7% |
| Q2 2026 | $73.4M | -8.7% |
| Q1 2026 | $75.6M | -21% |
| Q4 2025 | $74.9M | -38% |
| Q3 2025 | $70.8M | -49% |
| Q2 2025 | $80.4M | -51% |
| Q1 2025 | $96M | -50% |
| Q4 2024 | $120.8M | -39% |
DCGO's revenue has slid since its 2023 peak: $73M last quarter, up 3.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -24% | +36 points |
| Q2 2026 | -24% | -2.7 points |
| Q1 2026 | -25% | -10 points |
| Q4 2025 | -140% | -133 points |
| Q3 2025 | -59% | -67 points |
| Q2 2025 | -22% | -28 points |
| Q1 2025 | -15% | -23 points |
| Q4 2024 | -6.2% | -12 points |
DCGO's operating margin was −24% last quarter, up 36 points from the same quarter a year ago.
DCGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3.7M | -578% |
| Q2 2026 | -$9.6M | -129% |
| Q1 2026 | -$5.1M | -162% |
| Q4 2025 | -$12M | -200% |
| Q3 2025 | $782.6K | -97% |
| Q2 2025 | $32.9M | +2.1% |
| Q1 2025 | $8.2M | +$19.8M |
| Q4 2024 | $12M | +$21.1M |
DCGO's free cash flow was −$30M over the past year, against $54M the year before.
DCGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -3.5x | Net Cash |
| Q4 2024 | -1.8x | Net Cash |
| Q3 2024 | -1.6x | Net Cash |
| Q2 2024 | -1.2x | Net Cash |
| Q1 2024 | -0.9x | Net Cash |
| Q4 2023 | -2.2x | Net Cash |
| Q3 2023 | -2.7x | Net Cash |
| Q2 2023 | -8.4x | Net Cash |
DCGO has more cash than debt.
DCGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.6 | Oversold |
| Stochastic | 4.2 | Oversold |
DCGO's weekly RSI is 28 (oversold) and its Stochastic is 4 (oversold).
DCGO PE vs Healthcare Sector
| Metric | DCGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
DCGO has no meaningful PE right now: it lost money over the past year.
DCGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.29 | 21% below |
| 20 week MA | $0.43 | 47% below |
| 50 week MA | $0.60 | 62% below |
| 100 week MA | $1.44 | 84% below |
| 200 week MA | $3.57 | 94% below |
DCGO is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
DCGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.3 | $10.4 | +0.8% |
| 2021 | $10.4 | $8.71 | -16% |
| 2022 | $8.71 | $6.91 | -21% |
| 2023 | $6.91 | $5.59 | -19% |
| 2024 | $5.59 | $4.38 | -22% |
| 2025 | $4.38 | $0.93 | -79% |
| 2026 YTD | $0.93 | $0.23 | -75% |
DCGO has finished five years in a row lower, and it's down 75% so far in 2026.